Wed, Aug 27, 2014, 7:11 AM EDT - U.S. Markets open in 2 hrs 19 mins

Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, Inc. (CIGX) Message Board

crooked_analyst 27 posts  |  Last Activity: 15 hours ago Member since: May 22, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Rock Creek Pharmaceuticals, Inc. - Common Stock
    Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
    08/15/2014 16,986,960 (3.43) 1,223,421 13.88
    07/31/2014 17,590,749 (9.99) 1,073,322 16.39
    07/15/2014 19,542,142 (29.91) 887,945 22.01
    06/30/2014 27,879,988 2.65 3,041,589 9.17

  • crooked_analyst by crooked_analyst Aug 6, 2014 1:11 PM Flag

    Funny, neither of them has any Bankruptcy experience.... Guess they weren't brought on to wind down the company. Looks like two solid additions to navigate the waters through the FDA and the Investment world.

  • Reply to

    yeah, it was a bad day..............

    by abi_lgm_2007 Jul 28, 2014 11:20 PM
    crooked_analyst crooked_analyst Jul 29, 2014 12:24 AM Flag

    I agree for the most part, BUT for heaven's sake, get it right... It is McDonnell. Failure to do so makes it appear as somewhat uninformed. NOT trying to be nasty but it is important.

  • Reply to

    New Short Interest..... 8 million covered.

    by crooked_analyst Jul 24, 2014 4:03 PM
    crooked_analyst crooked_analyst Jul 25, 2014 9:46 AM Flag

    Likely a bought deal by one of the Banks and flipped to some of the parties that were short....

  • Rock Creek Pharmaceuticals, Inc. - Common Stock
    Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
    07/15/2014 19,542,142 (29.91) 887,945 22.01
    06/30/2014 27,879,988 2.65 3,041,589 9.17
    06/13/2014 27,160,895 2.49 756,018 35.93
    05/30/2014 26,501,971 3.53 944,548 28.06
    05/15/2014 25,599,352 (2.98) 562,469 45.51

  • Reply to

    Was former governor set up?

    by repo_man_one Jul 23, 2014 12:02 PM
    crooked_analyst crooked_analyst Jul 23, 2014 1:38 PM Flag

    Not to mention that it isn't setting someone up when the person fails to report a required action. JW didn't make BO not report the Loan or gifts.

  • crooked_analyst by crooked_analyst Jul 16, 2014 3:42 PM Flag

    Options Expiration is on Friday... and $.50 is the point of Maximum Pain. Look for a rug pull tomorrow and Friday.

  • Reply to

    FDA Comments are forthcoming

    by crooked_analyst Jul 11, 2014 4:33 PM
    crooked_analyst crooked_analyst Jul 11, 2014 6:04 PM Flag

    Review process
    Once the required three copies of the IND have been submitted,
    expect a call or an email from the project manager for additional
    copies. The project manager may ask for one additional copy or for
    twenty additional copies. Hopefully the reviewer will limit additional
    desk copies without the supporting study reports, but abiding by
    FDA requests for additional copies is highly advised. An official
    acknowledgement letter with the assigned IND number is commonly
    received within two weeks of submission.
    Questions and specific requests from the project manager may
    come during Weeks 3 and 4; similarly you may be alerted to exactly
    when the IND reviewing team will be gathering as a group and you
    may be asked to be ready to discuss matters with the reviewers. This
    meeting typically occurs around Day 28 or 29 of the 30-day review
    cycle. But you also have to be ready to receive an unannounced
    phone call at this time where the Division Director or the director’s
    representative will inform you of the division’s decision. Generally,
    this teleconference is not a time for negotiations; a decision has been
    made by the reviewing team, and the sponsor will have to abide by
    that decision.
    The comments to the IND come in two categories. The first
    category will be forward-looking comments and recommendations
    intended to help the submitted protocol and beyond for consideration
    by the sponsor. The second category consists of comments which are
    “Clinical Hold” issues that, unless you agree to make changes right on
    the call, the FDA will inform you that your study cannot be conducted.
    An example would be a required protocol modification affecting your
    inclusion/exclusion criteria.

  • Reply to

    PR Wording ~

    by a_brown3 Jul 11, 2014 5:14 PM
    crooked_analyst crooked_analyst Jul 11, 2014 5:27 PM Flag

    §312.41 Comment and advice on an IND.

    (a) FDA may at any time during the course of the investigation communicate with the sponsor orally or in writing about deficiencies in the IND or about FDA's need for more data or information.

    (b) On the sponsor's request, FDA will provide advice on specific matters relating to an IND. Examples of such advice may include advice on the adequacy of technical data to support an investigational plan, on the design of a clinical trial, and on whether proposed investigations are likely to produce the data and information that is needed to meet requirements for a marketing application.

    (c) Unless the communication is accompanied by a clinical hold order under §312.42, FDA communications with a sponsor under this section are solely advisory and do not require any modification in the planned or ongoing clinical investigations or response to the agency.

    [52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9586, Mar. 4, 2002]

  • Reply to

    FDA Comments are forthcoming

    by crooked_analyst Jul 11, 2014 4:33 PM
    crooked_analyst crooked_analyst Jul 11, 2014 4:42 PM Flag

    I hope you're right but I am skeptical that this is yet another roadblock being thrown in front of us. "...Dr. Chris Chapman, RCP's President, commented, "We appreciate the agency's review and comments on our IND. When we receive the agency's official comments and/or recommendations, we will respond expeditiously. We look forward to moving this important product through the regulatory process."

  • crooked_analyst by crooked_analyst Jul 11, 2014 4:33 PM Flag

    News just out....

  • Reply to

    This week

    by jk224_pmc Jul 11, 2014 1:37 PM
    crooked_analyst crooked_analyst Jul 11, 2014 2:16 PM Flag

    Market Makers include Goldman Sachs, Cantor Fitzgerald, Deutsche, Knight Capital, Group One and Susquehana. Need I say more?

  • crooked_analyst by crooked_analyst Jul 10, 2014 5:18 PM Flag

    Rock Creek Pharmaceuticals, Inc. - Common Stock
    Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
    06/30/2014 27,879,988 2.65 3,041,589 9.17
    06/13/2014 27,160,895 2.49 756,018 35.93
    05/30/2014 26,501,971 3.53 944,548 28.06
    05/15/2014 25,599,352 (2.98) 562,469 45.51
    04/30/2014 26,385,694 (3.23) 555,264 47.52

  • crooked_analyst by crooked_analyst Jul 8, 2014 1:27 PM Flag

    SETTLEMENT DATE|CUSIP|SYMBOL|QUANTITY (FAILS)|DESCRIPTION|PRICE

    20140604|772081105|RCPI|735667|ROCK CREEK PHARMACEUTICALS INC|1.00

    20140605|772081105|RCPI|66527|ROCK CREEK PHARMACEUTICALS INC|0.68

    20140606|772081105|RCPI|125894|ROCK CREEK PHARMACEUTICALS INC|0.65

    20140609|772081105|RCPI|152372|ROCK CREEK PHARMACEUTICALS INC|0.66

    20140610|772081105|RCPI|172823|ROCK CREEK PHARMACEUTICALS INC|0.72

    20140611|772081105|RCPI|110528|ROCK CREEK PHARMACEUTICALS INC|0.73

    20140612|772081105|RCPI|106536|ROCK CREEK PHARMACEUTICALS INC|0.77

    20140613|772081105|RCPI|116624|ROCK CREEK PHARMACEUTICALS INC|0.77

  • Reply to

    Interesting Question on iHub

    by repo_man_one Jul 1, 2014 12:33 PM
    crooked_analyst crooked_analyst Jul 1, 2014 12:39 PM Flag

    My guess is that there MUST be something somewhat materially different than Anatabloc, else they would likely have to pull from shelf while moving through the process.

  • Reply to

    From today's Article in Bradenton Herald

    by crooked_analyst Jun 18, 2014 12:31 PM
    crooked_analyst crooked_analyst Jun 18, 2014 1:08 PM Flag

    Bingo!

  • crooked_analyst by crooked_analyst Jun 18, 2014 12:31 PM Flag

    "We've cleaned up our act," Jenkins said.

    Anatabloc had been improperly marketed for Alzheimer's based on anecdotal testimonies, he said.

    However, the compound within the nutritional supplement showed promise, so the company is seeking FDA permission to begin drug testing trials to develop a drug to battle osteoarthritis, Jenkins said.

    "It was for the most part somewhat of a consumer nutritional supplements products company, and now we are pursuing an FDA regulatory drug pathway," Jenkins said of Rock Creek's shift as a company.

    Mullan's work with Alzheimer's, multiple sclerosis and other inflammatory-based diseases complement the basis of Rock Creek's anti-inflammatory developments, Jenkins added.

  • Reply to

    TIGHT CASH

    by frazier52 Jun 13, 2014 1:32 PM
    crooked_analyst crooked_analyst Jun 16, 2014 9:56 PM Flag

    I am a straight Cash Account with a no margin to avoid the borrow. I have been advised that simply placing a GTC order at a dollar figure is not sufficient unless you are in a cash account and direct the brokerage to place a not for borrow directive. I maintain 7 accounts and am operating under these guidelines. Anybody else?

  • Reply to

    Off by 1/10,000th on the Day

    by crooked_analyst Jun 13, 2014 2:24 PM
    crooked_analyst crooked_analyst Jun 13, 2014 3:55 PM Flag

    I guess this is what burying the 100 share at a time lots ends up looking like....Eventually, they have to report the trade.

    15:48:01 0.7414 96900 NDD

  • crooked_analyst by crooked_analyst Jun 13, 2014 2:24 PM Flag

    Helluva job by the Market Makers..... Almost as good as Options Expiration.

STSI
0.58010.0000(0.00%)Jun 3 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.